Source:http://linkedlifedata.com/resource/pubmed/id/18774728
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2008-11-10
|
pubmed:abstractText |
Primary mediastinal large B-cell lymphoma (PMLBCL) is a unique type of B-cell lymphoma probably arising from a putative thymic medulla B-cell. It constitutes 6-10% of all diffuse large B-cell lymphomas (DLBCL), occurring more often in young females. PMLBCL is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis and a degree of compartmentalisation. Its main molecular characteristics include: gains in 9p segments, p53 mutations, BCL-2 and MAL gene over-expression, somatic mutations of IgVH genes, BCL-6, PIM-1, PAX-5, RhoH/TTF, and c-MYC, and constitutional NF-kappaB activation. The gene expression signature of PMLBCL seems to be much closer to classic Hodgkin lymphoma than to DLBCL. PMLBCL is characterized by a locally invasive anterior mediastinal mass, often producing cough, chest pain, dyspnea, and superior vena cava syndrome. Most PMLBCL patients have stage I-II, bulky disease, with pleural or pericardial effusions in a third of cases. Systemic symptoms, mainly fever or weight loss, are present in <20% of cases; increased LDH levels are observed in 70-80% of cases. Treatment with CHOP regimen followed by radiation therapy was associated with a 5-year survival of 65%. Apparently better results have been reported with third-generation weekly alternating regimens followed by radiation therapy. Any recurrence is almost always seen in the first 2 years of follow-up, and distant relapses tend to involve extranodal organs. Features associated with poor prognosis are poor performance status, pericardial effusion, bulky disease, high serum LDH at diagnosis, and a compromised dose-intensity of anthracycline and cyclophosphamide.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1040-8428
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
68
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
256-63
|
pubmed:meshHeading |
pubmed-meshheading:18774728-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18774728-Cyclophosphamide,
pubmed-meshheading:18774728-Disease-Free Survival,
pubmed-meshheading:18774728-Doxorubicin,
pubmed-meshheading:18774728-Female,
pubmed-meshheading:18774728-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:18774728-Humans,
pubmed-meshheading:18774728-Lymphoma, B-Cell,
pubmed-meshheading:18774728-Male,
pubmed-meshheading:18774728-Mediastinal Neoplasms,
pubmed-meshheading:18774728-Neoplasm Proteins,
pubmed-meshheading:18774728-Pericardial Effusion,
pubmed-meshheading:18774728-Prednisone,
pubmed-meshheading:18774728-Survival Rate,
pubmed-meshheading:18774728-Vincristine
|
pubmed:year |
2008
|
pubmed:articleTitle |
Primary mediastinal large B-cell lymphoma.
|
pubmed:affiliation |
Department of Cellular Biotecnologies and Hematology, Division of Hematology, University La Sapienza, Rome, Italy.
|
pubmed:publicationType |
Journal Article,
Review
|